A randomized phase II trial of avastin (A) [bevacizumab] or avastin and erlotinib (AE) as first line consolidation chemotherapy after carboplatin, paclitaxel and avastin (CTA) induction therapy for newly diagnosed advanced ovarian, fallopian tube and primary peritoneal cancer and papillary serous mullerian tumours

Trial Profile

A randomized phase II trial of avastin (A) [bevacizumab] or avastin and erlotinib (AE) as first line consolidation chemotherapy after carboplatin, paclitaxel and avastin (CTA) induction therapy for newly diagnosed advanced ovarian, fallopian tube and primary peritoneal cancer and papillary serous mullerian tumours

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2013 Planned end date changed from 1 Jan 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top